Contact
searchSearch
HMP Global

Thrombectomy

Features

Interview
New MAUDE Analysis Highlights Real-World Mechanical Thrombectomy Complications
05/18/2026
Chloe Issa, MD; Sarah Montaquila, DO
Drs Issa and Montaquila discuss their analysis of FDA MAUDE data examining adverse events in venous and pulmonary mechanical thrombectomy systems.
Drs Issa and Montaquila discuss their analysis of FDA MAUDE data examining adverse events in venous and pulmonary mechanical thrombectomy systems.
Drs Issa and Montaquila discuss...
05/18/2026
Vascular Disease Management
Interview
New Insights on Thrombectomy in Atrial Fibrillation-Related Stroke
05/06/2026
Waseem Wahood, MD
Dr Wahood discusses trends reshaping the landscape of mechanical thrombectomy for acute ischemic stroke, particularly in patients with atrial fibrillation.
Dr Wahood discusses trends reshaping the landscape of mechanical thrombectomy for acute ischemic stroke, particularly in patients with atrial fibrillation.
Dr Wahood discusses trends...
05/06/2026
Vascular Disease Management
Dr Mouawad speaks at ISET 2026
ISET 2026
Advancing Thrombectomy and Autologous Blood Reinfusion for Pulmonary Embolism Treatment: Results from the AVENTUS Pivotal Study
04/09/2026
Nicolas J. Mouawad, MD, MPH, MBA
Dr Mouawad discusses the results of the AVENTUS pivotal trial.
Dr Mouawad discusses the results of the AVENTUS pivotal trial.
Dr Mouawad discusses the results...
04/09/2026
Vascular Disease Management
Endovascular Devices
Thrombolex, Inc. Secures $50 Million Series A Growth Financing to Advance Commercialization of its Innovative Pharmaco-Mechanical Lysis Technology (PML)
03/19/2026
New Britain, PA, March 16, 2026 – Thrombolex, Inc., a commercial-stage medical device company advancing a differentiated pharmaco-mechanical lysis (PML) platform for the treatment of pulmonary embolism (PE) and other thromboembolic diseases,...
New Britain, PA, March 16, 2026 – Thrombolex, Inc., a commercial-stage medical device company advancing a differentiated pharmaco-mechanical lysis (PML) platform for the treatment of pulmonary embolism (PE) and other thromboembolic diseases,...
New Britain, PA, March 16, 2026...
03/19/2026
Vascular Disease Management
Original Research
Temporary Occlusion Embolectomy: A Cost-Effective Approach to Distal Embolic Protection in Peripheral Artery Disease
03/18/2026
Tom Davis, MD; Peter Dovgan, MD; Eric J. Dippel, MD
This retrospective observational case series evaluated embolic debris retrieval and procedural feasibility of temporary occlusion embolectomy during complex peripheral vascular interventions.
This retrospective observational case series evaluated embolic debris retrieval and procedural feasibility of temporary occlusion embolectomy during complex peripheral vascular interventions.
This retrospective observational...
03/18/2026
Vascular Disease Management
Sean P. Lyden, MD
ISET 2026
Real-World Acute Limb Ischemia: What the PROWL Registry Is Teaching Us
02/10/2026
Sean P. Lyden, MD
Sean P. Lyden, MD, discussed new real-world data from the PROWL Registry, offering a look at how acute, subacute, and CLTI are being treated outside the confines of traditional clinical trial exclusions.
Sean P. Lyden, MD, discussed new real-world data from the PROWL Registry, offering a look at how acute, subacute, and CLTI are being treated outside the confines of traditional clinical trial exclusions.
Sean P. Lyden, MD, discussed new...
02/10/2026
Vascular Disease Management
Interview
Mechanical Computer-Assisted Aspiration Thrombectomy Using the Indigo System: Latest Results From the STRIDE Multicenter Trial
02/03/2026
Thomas Maldonado, MD
Dr Maldonado discusses the design and significance of the STRIDE trial, highlights key findings, and explains how these data may inform endovascular treatment strategies.
Dr Maldonado discusses the design and significance of the STRIDE trial, highlights key findings, and explains how these data may inform endovascular treatment strategies.
Dr Maldonado discusses the...
02/03/2026
Vascular Disease Management
marianne brodmann
LINC 2026
Mechanical Thrombectomy or Thrombolysis Treatment of Pulmonary Embolism: What Is State of the Art In 2026?
01/26/2026
Marianne Brodmann, MD
Marianne Brodmann reflects on where the balance lies in 2026, what drives modality choice at the bedside, and what data gaps still limit decision-making.
Marianne Brodmann reflects on where the balance lies in 2026, what drives modality choice at the bedside, and what data gaps still limit decision-making.
Marianne Brodmann reflects on...
01/26/2026
Vascular Disease Management
Interview
Are Lytic-Based Thrombectomy Devices Still Relevant?
01/12/2026
Nicolas J. Mouawad, MD, MPH, MBA
Nicolas J. Mouawad, MD, asks if lytic-based thrombectomy is still relevant and discusses how non–lytic-based therapies provide a better safety profile and lower bleeding risk.
Nicolas J. Mouawad, MD, asks if lytic-based thrombectomy is still relevant and discusses how non–lytic-based therapies provide a better safety profile and lower bleeding risk.
Nicolas J. Mouawad, MD, asks if...
01/12/2026
Vascular Disease Management

Videos

Dr Mouawad speaks at ISET 2026
ISET 2026
Advancing Thrombectomy and Autologous Blood Reinfusion for Pulmonary Embolism Treatment: Results from the AVENTUS Pivotal Study
04/09/2026
Nicolas J. Mouawad, MD, MPH, MBA
Dr Mouawad discusses the results of the AVENTUS pivotal trial.
Dr Mouawad discusses the results of the AVENTUS pivotal trial.
Dr Mouawad discusses the results...
04/09/2026
Vascular Disease Management
Dr Constantino Pena
AMP 2024
High Limb Salvage Rate and Improved Quality of Life Following Aspiration Thrombectomy With Indigo for Lower-Extremity Acute Limb Ischemia
09/11/2024
Constantino S. Peña, MD, FAHA, FSCCT, FSIR
Watch as Dr. Constantino Peña discusses his AMP presentation on the 12-month results from the STRIDE study.
Watch as Dr. Constantino Peña discusses his AMP presentation on the 12-month results from the STRIDE study.
Watch as Dr. Constantino Peña...
09/11/2024
Vascular Disease Management
Dr Lichtenberg
ISET 2024
Final Subgroup Analysis From the Rotarex Post-Market Study
03/06/2024
Michael Lichtenberg, MD, FESC
Dr. Michael Lichtenberg discusses his presentation on the Rotarex Post-Market Study at ISET 2024.
Dr. Michael Lichtenberg discusses his presentation on the Rotarex Post-Market Study at ISET 2024.
Dr. Michael Lichtenberg...
03/06/2024
Vascular Disease Management
Dr Lichtenberg
AMP 2023
24-Month Results From the Prospective Multicenter Study of the Rotarex Atherectomy and Thrombectomy Catheter System
12/11/2023
Michael Lichtenberg, MD, FESC
Dr. Michael Lichtenberg discusses his presentation on the latest results from a European trial analyzing the efficacy and safety of the Rotarex device (BD) for patients with femoropopliteal disease.
Dr. Michael Lichtenberg discusses his presentation on the latest results from a European trial analyzing the efficacy and safety of the Rotarex device (BD) for patients with femoropopliteal disease.
Dr. Michael Lichtenberg...
12/11/2023
Vascular Disease Management
Video
COVID-19 and Cardiovascular Complications: Unanswered Questions Remain
03/27/2023
Craig M. Walker, MD, FACC, FACP, FSCAI, FCCP
Dr. Walker comments on “Acute Limb Ischemia as a Complication of COVID-19.” He discusses the authors' findings and addresses the many unanswered questions that remain about COVID-19 and cardiovascular complications.
Dr. Walker comments on “Acute Limb Ischemia as a Complication of COVID-19.” He discusses the authors' findings and addresses the many unanswered questions that remain about COVID-19 and cardiovascular complications.
Dr. Walker comments on “Acute...
03/27/2023
Vascular Disease Management
Dr Mathews
ISET 2023
The Current State of DVT Therapy and an Update on Devices
02/28/2023
S. Jay Mathews, MD, MS, FACC, FSCAI
In this video, Dr. S. Jay Mathews from Bradenton Cardiology Center in Bradenton, Florida, discusses his ISET 2023 presentations on the DEEPER Reveal Study and the latest devices for DVT therapies.
In this video, Dr. S. Jay Mathews from Bradenton Cardiology Center in Bradenton, Florida, discusses his ISET 2023 presentations on the DEEPER Reveal Study and the latest devices for DVT therapies.
In this video, Dr. S. Jay...
02/28/2023
Vascular Disease Management
Dr Sista
ISET 2023
The Current State of PE Therapy
02/28/2023
Akhilesh K. Sista, MD
Interventional radiologist Akhi Sista, MD, from Weill Cornell Medicine in New York, discusses his ISET 2023 presentations on endovascular pulmonary embolism interventions. 
Interventional radiologist Akhi Sista, MD, from Weill Cornell Medicine in New York, discusses his ISET 2023 presentations on endovascular pulmonary embolism interventions. 
Interventional radiologist Akhi...
02/28/2023
Vascular Disease Management
Video
Leveraging Thrombectomy Tools to Achieve Flow Restoration
01/20/2023
S. Jay Mathews, MD, MS, FACC, FSCAI
Dr. S. Jay Mathews discusses “Patency Restored to an Occluded Femoralfemoral Venous Bypass Graft With the ClotTriever Thrombectomy System" by Mohannad Bisharat, MD.
Dr. S. Jay Mathews discusses “Patency Restored to an Occluded Femoralfemoral Venous Bypass Graft With the ClotTriever Thrombectomy System" by Mohannad Bisharat, MD.
Dr. S. Jay Mathews discusses...
01/20/2023
Vascular Disease Management
NCVH 2022
Dr. S. Jay Mathews at NCVH 2022
06/02/2022
Dr. S. Jay Mathews, interventional cardiologist from Bradenton, Florida, discusses a few of his NCVH presentations on venous therapies, novel technologies for performing thrombectomy, 5-year data from the Stellarex study, and limb salvage.
Dr. S. Jay Mathews, interventional cardiologist from Bradenton, Florida, discusses a few of his NCVH presentations on venous therapies, novel technologies for performing thrombectomy, 5-year data from the Stellarex study, and limb salvage.
Dr. S. Jay Mathews,...
06/02/2022
Vascular Disease Management
Ghassan Abou-Alfa headshot
ASCO 2026
Immunotherapy Plus TACE Emerges as a New Option for Intermediate-Stage Hepatocellular Carcinoma
07/13/2026
Ghassan Abou-Alfa, MD, MBA
Ghassan Abou-Alfa, MD, discusses phase 3 EMERALD-3 results showing that adding STRIDE (tremelimumab plus durvalumab) to transarterial chemoembolization significantly improved progression-free survival in patients with unresectable...
Ghassan Abou-Alfa, MD, discusses phase 3 EMERALD-3 results showing that adding STRIDE (tremelimumab plus durvalumab) to transarterial chemoembolization significantly improved progression-free survival in patients with unresectable...
Ghassan Abou-Alfa, MD, discusses...
07/13/2026
Vascular Disease Management
Michael Pishvaian headshot
Interview
Intra-Arterial Gemcitabine for Patients With Locally Advanced Pancreatic Cancer
06/15/2026
Michael Pishvaian, MD, PhD
Michael Pishvaian, MD, PhD, discusses the phase 3 TIGeR-PaC study evaluating intra-arterial gemcitabine among patients with locally advanced pancreatic cancer.
Michael Pishvaian, MD, PhD, discusses the phase 3 TIGeR-PaC study evaluating intra-arterial gemcitabine among patients with locally advanced pancreatic cancer.
Michael Pishvaian, MD, PhD,...
06/15/2026
Vascular Disease Management
Dr Kak Khee Yeung speaks at ISET 2026.
ISET 2026
Can AI Be of Value in Predicting Type B Dissection Progression Over Time?
04/16/2026
Kak Khee Yeung, MD, PhD
Kak Khee Yeung, MD, PhD, explores the potential role of AI in predicting the progression of Type B aortic dissection over time.
Kak Khee Yeung, MD, PhD, explores the potential role of AI in predicting the progression of Type B aortic dissection over time.
Kak Khee Yeung, MD, PhD,...
04/16/2026
Vascular Disease Management
Dr Mouawad speaks at ISET 2026
ISET 2026
Advancing Thrombectomy and Autologous Blood Reinfusion for Pulmonary Embolism Treatment: Results from the AVENTUS Pivotal Study
04/09/2026
Nicolas J. Mouawad, MD, MPH, MBA
Dr Mouawad discusses the results of the AVENTUS pivotal trial.
Dr Mouawad discusses the results of the AVENTUS pivotal trial.
Dr Mouawad discusses the results...
04/09/2026
Vascular Disease Management
Dr S Jay Mathews speaks at ISET 2026
ISET 2026
Retrievable Scaffold Therapy: Results From Trials
04/07/2026
S. Jay Mathews, MD, MS, FACC, FSCAI
Dr Mathews reviews the latest clinical data, discusses evolving techniques, and highlights how retrievable scaffold technology is shaping the future of vascular intervention.
Dr Mathews reviews the latest clinical data, discusses evolving techniques, and highlights how retrievable scaffold technology is shaping the future of vascular intervention.
Dr Mathews reviews the latest...
04/07/2026
Vascular Disease Management
Dr Mary Costantino speaks at ISET 2026.
ISET 2026
Uterine Fibroid Embolization in the OBL: Patient Selection and Workflow Optimization
04/02/2026
Mary Costantino, MD, FSIR
Dr Costantino outlines practical strategies for identifying appropriate candidates and streamlining procedural workflows in the OBL setting, with a focus on improving efficiency, patient outcomes, and overall practice success.
Dr Costantino outlines practical strategies for identifying appropriate candidates and streamlining procedural workflows in the OBL setting, with a focus on improving efficiency, patient outcomes, and overall practice success.
Dr Costantino outlines practical...
04/02/2026
Vascular Disease Management
Dr Salazar speaks at ISET 2026
ISET 2026
Venous Valve Technology: When Will It Be Standard of Care?
04/01/2026
Gloria Salazar, MD, FSIR
Dr Salazar examines the current state of venous valve technologies, including recent clinical progress and the challenges that remain before widespread adoption.
Dr Salazar examines the current state of venous valve technologies, including recent clinical progress and the challenges that remain before widespread adoption.
Dr Salazar examines the current...
04/01/2026
Vascular Disease Management
Dr Gunnar Tepe speaks at ISET 2026
ISET 2026
The State of DCB Technology in 2026: Where Are We Going?
03/31/2026
Gunnar Tepe, MD
Dr. Tepe explores the latest clinical data, emerging innovations, and ongoing challenges shaping the field, offering insight into how DCB technology is redefining endovascular treatment strategies today—and where it may lead.
Dr. Tepe explores the latest clinical data, emerging innovations, and ongoing challenges shaping the field, offering insight into how DCB technology is redefining endovascular treatment strategies today—and where it may lead.
Dr. Tepe explores the latest...
03/31/2026
Vascular Disease Management
Dr Jacques Busquet speaks at ISET 2026.
ISET 2026
The Mystery of Post-EVAR Endotension
03/26/2026
Jacques Busquet, MD
In this video, renowned cardiovascular and endovascular surgeon Jacques Busquet, MD, from Clinique Val d'Or in Paris, France, explores the mystery of post-EVAR endotension, expanding on insights from his presentation at ISET 2026.
In this video, renowned cardiovascular and endovascular surgeon Jacques Busquet, MD, from Clinique Val d'Or in Paris, France, explores the mystery of post-EVAR endotension, expanding on insights from his presentation at ISET 2026.
In this video, renowned...
03/26/2026
Vascular Disease Management
Dr Sanjay Misra speaks at ISET 2026
ISET 2026
Renal Denervation for Refractory Hypertension: Indications, Data, and Outcomes
03/25/2026
Sanjay Misra, MD, FSIR, FAHA, FACR
Interventional radiologist Sanjay Misra, MD, FSIR, FAHA, FACR, from the Mayo Clinic, highlights key insights from his presentation on renal denervation for hypertension.
Interventional radiologist Sanjay Misra, MD, FSIR, FAHA, FACR, from the Mayo Clinic, highlights key insights from his presentation on renal denervation for hypertension.
Interventional radiologist...
03/25/2026
Vascular Disease Management

Presentations

Sean P. Lyden, MD
ISET 2026
Real-World Acute Limb Ischemia: What the PROWL Registry Is Teaching Us
02/10/2026
Sean P. Lyden, MD
Sean P. Lyden, MD, discussed new real-world data from the PROWL Registry, offering a look at how acute, subacute, and CLTI are being treated outside the confines of traditional clinical trial exclusions.
Sean P. Lyden, MD, discussed new real-world data from the PROWL Registry, offering a look at how acute, subacute, and CLTI are being treated outside the confines of traditional clinical trial exclusions.
Sean P. Lyden, MD, discussed new...
02/10/2026
Vascular Disease Management
marianne brodmann
LINC 2026
Mechanical Thrombectomy or Thrombolysis Treatment of Pulmonary Embolism: What Is State of the Art In 2026?
01/26/2026
Marianne Brodmann, MD
Marianne Brodmann reflects on where the balance lies in 2026, what drives modality choice at the bedside, and what data gaps still limit decision-making.
Marianne Brodmann reflects on where the balance lies in 2026, what drives modality choice at the bedside, and what data gaps still limit decision-making.
Marianne Brodmann reflects on...
01/26/2026
Vascular Disease Management
Dr Lookstein
LINC 2024
The Future of Treatment of Venous Thromboembolism Is Single-session/On-table Therapy
05/30/2024
Robert A. Lookstein, MD
The future of venous thrombosis treatment was tackled in a VIVA@LINC session by Robert Lookstein, MD, Professor of Radiology and Surgery at the Icahn School of Medicine at Mount Sinai in New York City.
The future of venous thrombosis treatment was tackled in a VIVA@LINC session by Robert Lookstein, MD, Professor of Radiology and Surgery at the Icahn School of Medicine at Mount Sinai in New York City.
The future of venous thrombosis...
05/30/2024
Vascular Disease Management
Dr Manuela Konert
LINC 2024
Can Post-thrombotic Syndrome Be Prevented?
05/28/2024

Manuela Konert, MD
University Hospital Leipzig, Germany

Manuela Konert, MD University Hospita...
The case for mechanical thrombectomy as a means to eliminate post-thrombotic syndrome (PTS) was discussed today by Manuela Konert, a consultant interventionalist and head of the venous centre at University Hospital Leipzig, Germany. 
The case for mechanical thrombectomy as a means to eliminate post-thrombotic syndrome (PTS) was discussed today by Manuela Konert, a consultant interventionalist and head of the venous centre at University Hospital Leipzig, Germany. 
The case for mechanical...
05/28/2024
Vascular Disease Management
Michael Lichtenberg MD
LINC 2024
Aspirex Could Push Through to New Era in Mechanical Thrombectomy
05/28/2024

Michael Lichtenberg, MD
Arnsberg Vascular Clinic, Arnsberg, Germany

Michael Lichtenberg, MD Arnsberg Vasc...
A study of a mechanical thrombectomy device in the treatment of acute venous occlusions was given a 24-month update today by Michael Lichtenberg, an interventional radiologist and head of the Arnsberg Vascular Clinic.
A study of a mechanical thrombectomy device in the treatment of acute venous occlusions was given a 24-month update today by Michael Lichtenberg, an interventional radiologist and head of the Arnsberg Vascular Clinic.
A study of a mechanical...
05/28/2024
Vascular Disease Management
Dr Desai
LINC 2023
Thrombectomy for DVT: Tips on Patient Selection and Procedure
06/07/2023
Kush Desai, MD
The questions of when and how to employ thrombectomy for DVT were addressed by Dr Kush Desai during a VIVA@LINC session on Wednesday.
The questions of when and how to employ thrombectomy for DVT were addressed by Dr Kush Desai during a VIVA@LINC session on Wednesday.
The questions of when and how to...
06/07/2023
Vascular Disease Management
Dr Gary Ansel
LINC 2023
FlowTriever Embolectomy for Acute Pulmonary Embolism
06/06/2023
Dr Gary Ansel discusses the FlowTriever System (Inari Medical), the first mechanical thrombectomy device indicated for the treatment of pulmonary embolism.
Dr Gary Ansel discusses the FlowTriever System (Inari Medical), the first mechanical thrombectomy device indicated for the treatment of pulmonary embolism.
Dr Gary Ansel discusses the...
06/06/2023
Vascular Disease Management
Mike Watts, MD, FSIR
AMP 2026
When Economics Meets Innovation: Matching Deep Venous Arterialization to the Right Site of Service
08/07/2026
Mike Watts, MD, FSIR
08/07/2026
Vascular Disease Management
Dr Yana Etkin
AMP 2026
Early Detection and Timely Reintervention Drive Success After Deep Venous Arterialization
08/07/2026
Yana Etkin, MD, FSVS, FACS
Yana Etkin, MD,  presented an in-depth review of strategies for identifying and managing failing DVA, emphasizing that long-term success depends not only on creating the DVA circuit but also on maintaining its patency through vigilant...
Yana Etkin, MD,  presented an in-depth review of strategies for identifying and managing failing DVA, emphasizing that long-term success depends not only on creating the DVA circuit but also on maintaining its patency through vigilant...
Yana Etkin, MD,  presented an...
08/07/2026
Vascular Disease Management
Alik Farber, MD
AMP 2026
Four-Year BEST-CLI Data Reinforce a Team-Based Future for Limb Salvage
08/07/2026
Alik Farber, MD
Alik Farber, MD, MBA, presented the latest 4-year findings from the landmark BEST-CLI trial. He challenged attendees to move beyond the long-standing debate of surgery vs endovascular intervention and instead embrace an evidence-based,...
Alik Farber, MD, MBA, presented the latest 4-year findings from the landmark BEST-CLI trial. He challenged attendees to move beyond the long-standing debate of surgery vs endovascular intervention and instead embrace an evidence-based,...
Alik Farber, MD, MBA, presented...
08/07/2026
Vascular Disease Management
Dr Eric Secemsky
AMP 2026
Defining Optimal Medical Therapy for CLTI in 2026
08/07/2026
Eric A. Secemsky, MD, MSc, RPVI, FACC, FAHA, FSCAI
Dr Eric Secemsky presented a review of the evidence supporting contemporary medical management for patients with PAD and CLTI, emphasizing that pharmacologic therapy remains an essential pillar of reducing cardiovascular events.
Dr Eric Secemsky presented a review of the evidence supporting contemporary medical management for patients with PAD and CLTI, emphasizing that pharmacologic therapy remains an essential pillar of reducing cardiovascular events.
Dr Eric Secemsky presented a...
08/07/2026
Vascular Disease Management
Dr Ralf Langhoff
AMP 2026
Retrograde Access Moves to the Forefront: Rethinking CTO Crossing Strategies
08/06/2026
Ralf Langhoff, MD
During a Thursday afternoon session at the Amputation Prevention Symposium 2026, Ralf Langhoff, MD, asked attendees to reconsider when retrograde access should be used for chronic total occlusion (CTO) interventions.
During a Thursday afternoon session at the Amputation Prevention Symposium 2026, Ralf Langhoff, MD, asked attendees to reconsider when retrograde access should be used for chronic total occlusion (CTO) interventions.
During a Thursday afternoon...
08/06/2026
Vascular Disease Management
Dr Ramon Varcoe
AMP 2026
Bioresorbable Below-the-Knee Technology Shows Durable Promise for CLTI
08/06/2026
Ramon L. Varcoe, MBBS, MS, PhD
Dr Ramon L. Varcoe presented an update on bioresorbable BTK technology, highlighting the growing body of evidence supporting the Esprit™ BTK drug-eluting resorbable scaffold (Abbott Cardiovascular) for the treatment of CLTI.
Dr Ramon L. Varcoe presented an update on bioresorbable BTK technology, highlighting the growing body of evidence supporting the Esprit™ BTK drug-eluting resorbable scaffold (Abbott Cardiovascular) for the treatment of CLTI.
Dr Ramon L. Varcoe presented an...
08/06/2026
Vascular Disease Management
Dr Pradeep Nair
AMP 2026
A New Approach to Crossing and Preparing Complex Peripheral Chronic Total Occlusions
08/06/2026
Pradeep K. Nair, MD, FACC, FSCAI
Dr Pradeep K. Nair presented the clinical rationale, engineering design, pivotal clinical data, and early real-world experience with the Santreva-ATK Endovascular Revascularization Catheter (AngioSafe).
Dr Pradeep K. Nair presented the clinical rationale, engineering design, pivotal clinical data, and early real-world experience with the Santreva-ATK Endovascular Revascularization Catheter (AngioSafe).
Dr Pradeep K. Nair presented the...
08/06/2026
Vascular Disease Management
S Jay Mathews, MD
AMP 2026
SELUTION SLR Highlights the Growing Role of Sirolimus Drug-Eluting Balloons in CLTI
08/06/2026
S. Jay Mathews, MD, MS, FACC, FSCAI
This presentation examined the evolving evidence supporting the SELUTION SLR sirolimus drug-eluting balloon (Cordis) as a treatment strategy for femoropopliteal and BTK PAD, with particular emphasis on complex CLTI.
This presentation examined the evolving evidence supporting the SELUTION SLR sirolimus drug-eluting balloon (Cordis) as a treatment strategy for femoropopliteal and BTK PAD, with particular emphasis on complex CLTI.
This presentation examined the...
08/06/2026
Vascular Disease Management
Tim Wittig, MD
AMP 2026
MOTIV BTK Trial Demonstrates Promising Early Outcomes for Sirolimus-Eluting Bioresorbable Scaffold in CLTI
08/05/2026
Tim Wittig, MD
Tim Wittig, MD, presents the primary outcomes from the MOTIV BTK Trial, which evaluated the safety and efficacy of the sirolimus-eluting bioresorbable scaffold MOTIV BTK.
Tim Wittig, MD, presents the primary outcomes from the MOTIV BTK Trial, which evaluated the safety and efficacy of the sirolimus-eluting bioresorbable scaffold MOTIV BTK.
Tim Wittig, MD, presents the...
08/05/2026
Vascular Disease Management
Dr Eric Scott
AMP 2026
Using Imaging to Choose Between Endovascular Therapy and Surgical Bypass
08/05/2026
Eric C. Scott, MD
Dr Eric Scott presents presents a case-based discussion on how advanced vascular imaging should guide the decision between an endovascular-first or surgical bypass-first approach for patients with PAD and CLTI.
Dr Eric Scott presents presents a case-based discussion on how advanced vascular imaging should guide the decision between an endovascular-first or surgical bypass-first approach for patients with PAD and CLTI.
Dr Eric Scott presents presents...
08/05/2026
Vascular Disease Management

Stay in the Know

Vascular Disease Management Newsletter

News

Endovascular Devices
Thrombolex, Inc. Secures $50 Million Series A Growth Financing to Advance Commercialization of its Innovative Pharmaco-Mechanical Lysis Technology (PML)
03/19/2026
New Britain, PA, March 16, 2026 – Thrombolex, Inc., a commercial-stage medical device company advancing a differentiated pharmaco-mechanical lysis (PML) platform for the treatment of pulmonary embolism (PE) and other thromboembolic diseases,...
New Britain, PA, March 16, 2026 – Thrombolex, Inc., a commercial-stage medical device company advancing a differentiated pharmaco-mechanical lysis (PML) platform for the treatment of pulmonary embolism (PE) and other thromboembolic diseases,...
New Britain, PA, March 16, 2026...
03/19/2026
Vascular Disease Management
Aspiration Thrombectomy
US Aspiration Thrombectomy Market Sees Rapid Growth in Recent Years, says GlobalData
04/30/2025
28 April 2025—Acute ischemic strokes afflict millions of people across the world every year, and the incidence of this life-threatening medical event continues to rise, driven by higher rates of hypertension and other comorbidities. The clots...
28 April 2025—Acute ischemic strokes afflict millions of people across the world every year, and the incidence of this life-threatening medical event continues to rise, driven by higher rates of hypertension and other comorbidities. The clots...
28 April 2025—Acute ischemic...
04/30/2025
Vascular Disease Management
thrombectomy
Seven New Data Sets Demonstrate Penumbra’s Computer Assisted Vacuum Thrombectomy (CAVT) Technology Is Safe, Fast and Effective, Improves Patient Outcomes, and Delivers Healthcare Resource Benefits
04/07/2025
Penumbra, Inc, announced seven significant computer assisted vacuum thrombectomy (CAVT™) data presentations during the 2025 Society of Interventional Radiology (SIR) Annual Scientific Meeting. The data showed that CAVT as a frontline therapy...
Penumbra, Inc, announced seven significant computer assisted vacuum thrombectomy (CAVT™) data presentations during the 2025 Society of Interventional Radiology (SIR) Annual Scientific Meeting. The data showed that CAVT as a frontline therapy...
Penumbra, Inc, announced seven...
04/07/2025
Cath Lab Digest
Thrombectomy
Inquis Medical Completes Enrollment in U.S. Pivotal IDE Trial of the Aventus Thrombectomy System Designed to Treat Patients With Pulmonary Embolism
01/13/2025
MENLO PARK, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Inquis Medical, a leading innovator in venous thromboembolic disease treatment, today announced completion of patient enrollment in its AVENTUS Clinical Trial, a pivotal Investigational...
MENLO PARK, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Inquis Medical, a leading innovator in venous thromboembolic disease treatment, today announced completion of patient enrollment in its AVENTUS Clinical Trial, a pivotal Investigational...
MENLO PARK, Calif., Jan. 13,...
01/13/2025
Vascular Disease Management
Late-Breaking Trials
Final Round of Late-Breaking Clinical Trial Results Announced at VIVA24
11/06/2024
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the final round of Late-Breaking Clinical Trials presented at...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the final round of Late-Breaking Clinical Trials presented at...
The VIVA Foundation, a...
11/06/2024
Vascular Disease Management
Late-Breaking Trials
Second Round of Late-Breaking Clinical Trial Results Announced at VIVA24
11/04/2024
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the second of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the second of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a...
11/04/2024
Vascular Disease Management
Pulmonary Embolism
Akura Medical Secures FDA Approval for US Pivotal Trial in Pulmonary Embolism
11/04/2024
The US FDA has approved its IDE application to initiate the QUADRA-PE study (NCT06672510) evaluating the Katana™ Thrombectomy System in patients with acute PE.
The US FDA has approved its IDE application to initiate the QUADRA-PE study (NCT06672510) evaluating the Katana™ Thrombectomy System in patients with acute PE.
The US FDA has approved its IDE...
11/04/2024
Vascular Disease Management
Deep Vein Thrombosis
CIS Is First in Louisiana to Use the Venacore™ Thrombectomy Catheter to Treat Deep Vein Disease
06/07/2024

CIS Press Release

CIS Press Release
HOUMA, LA – Dr. Matthew Finn, interventional cardiologist at Cardiovascular Institute of the South (CIS), is the first in Louisiana to use the VenaCore™ thrombectomy catheter to remove challenging venous occlusions in patients suffering from...
HOUMA, LA – Dr. Matthew Finn, interventional cardiologist at Cardiovascular Institute of the South (CIS), is the first in Louisiana to use the VenaCore™ thrombectomy catheter to remove challenging venous occlusions in patients suffering from...
HOUMA, LA – Dr. Matthew Finn,...
06/07/2024
Vascular Disease Management
Aspiration Thrombectomy
Innovative Aspiration Thrombectomy System by Expanse ICE Receives FDA Clearance for Vessels of the Peripheral Arterial and Venous Systems
04/22/2024

Expanse Medical Press Release

Expanse Medical Press Release
PLEASANTON, Calif., April 22, 2024 /PRNewswire/ -- Expanse ICE announced today the ICE Aspiration System has received 510(k) clearance from the U.S. Food and Drug Administration. This announcement introduces a new and exciting player in the...
PLEASANTON, Calif., April 22, 2024 /PRNewswire/ -- Expanse ICE announced today the ICE Aspiration System has received 510(k) clearance from the U.S. Food and Drug Administration. This announcement introduces a new and exciting player in the...
PLEASANTON, Calif., April 22,...
04/22/2024
Vascular Disease Management
News
Akura Medical Announces Successful First-in-Human Use of its High Performance Mechanical Thrombectomy Platform
05/10/2023
Initial cases, proctored by 2 leading US interventionalists, mark the first use of mechanical thrombectomy for pulmonary embolism in the Republic of Georgia Akura’s platform, which will be featured at PCR Innovator’s Day, uses a...
Initial cases, proctored by 2 leading US interventionalists, mark the first use of mechanical thrombectomy for pulmonary embolism in the Republic of Georgia Akura’s platform, which will be featured at PCR Innovator’s Day, uses a...
Initial cases, proctored by 2...
05/10/2023
Vascular Disease Management
Press Release
Fluidx Completes Submission of Premarket Approval Application for the GPX® Embolic Device
07/24/2026
Salt Lake City (UT) – 07/24/2026 Fluidx Medical Technology, Inc., a clinical stage medical device company advancing its portfolio of embolic technologies, announced that it recently submitted to the U.S. Food and Drug Administration (FDA) the...
Salt Lake City (UT) – 07/24/2026 Fluidx Medical Technology, Inc., a clinical stage medical device company advancing its portfolio of embolic technologies, announced that it recently submitted to the U.S. Food and Drug Administration (FDA) the...
Salt Lake City (UT) – 07/24/2026...
07/24/2026
Vascular Disease Management
Thrombectomy
THUNDER Study Demonstrates Penumbra’s THUNDERBOLT is Safe and Effective for Stroke Care
07/22/2026
ALAMEDA, Calif. – Penumbra, Inc. announced the results of THUNDER, an Investigational Device Exemption (IDE) study, to evaluate the safety and effectiveness of THUNDERBOLT™, the company’s novel...
ALAMEDA, Calif. – Penumbra, Inc. announced the results of THUNDER, an Investigational Device Exemption (IDE) study, to evaluate the safety and effectiveness of THUNDERBOLT™, the company’s novel...
ALAMEDA, Calif....
07/22/2026
Cath Lab Digest
Stroke Interventions
Imperative Care Launches Ikon 24 Pro Guidewire, Enhancing the Zoom Stroke System to Support More Efficient Stroke Procedures
07/17/2026
CAMPBELL, Calif., July 16, 2026 — Imperative Care, a medical technology company focused on advancing treatments for patients suffering from thromboembolic disease, today announced the launch of the Ikon™ 24 Pro Guidewire, a next-generation...
CAMPBELL, Calif., July 16, 2026 — Imperative Care, a medical technology company focused on advancing treatments for patients suffering from thromboembolic disease, today announced the launch of the Ikon™ 24 Pro Guidewire, a next-generation...
CAMPBELL, Calif., July 16, 2026...
07/17/2026
Vascular Disease Management
Liver Tumor Ablation
First Meta-analysis Supports Histotripsy for Liver Tumor Ablation
07/14/2026
Laura Simson, MA
Histotripsy demonstrated high technical success and an encouraging safety profile for the treatment of primary and secondary liver tumors in the first systematic review and meta-analysis to report the technology's clinical evidence.
Histotripsy demonstrated high technical success and an encouraging safety profile for the treatment of primary and secondary liver tumors in the first systematic review and meta-analysis to report the technology's clinical evidence.
Histotripsy demonstrated high...
07/14/2026
Vascular Disease Management
Radiation Safety
Landmark Multi-Society Consensus Signals New Era in Occupational Radiation Safety; Rampart Positioned to Accelerate Adoption of Lead-Free Enhanced Radiation Protection
07/14/2026
BIRMINGHAM, Ala. — July 14, 2026 — Rampart, the global leader in enhanced radiation protection devices (ERPD), today welcomed the publication of a landmark multi-society expert consensus statement that calls for a fundamental shift in...
BIRMINGHAM, Ala. — July 14, 2026 — Rampart, the global leader in enhanced radiation protection devices (ERPD), today welcomed the publication of a landmark multi-society expert consensus statement that calls for a fundamental shift in...
BIRMINGHAM, Ala. — July 14, 2026...
07/14/2026
Vascular Disease Management
GPX Embolic Device
GPX® Embolic Device Meets Primary Endpoints in an Investigational Device Exemption (IDE) Pivotal Trial
07/14/2026
Salt Lake City (UT) – Fluidx Medical Technology, Inc. announced the positive results from the Investigational Device Exemption (IDE) pivotal clinical trial evaluating the GPX Embolic Device. In the 114 patients that were treated in the trial,...
Salt Lake City (UT) – Fluidx Medical Technology, Inc. announced the positive results from the Investigational Device Exemption (IDE) pivotal clinical trial evaluating the GPX Embolic Device. In the 114 patients that were treated in the trial,...
Salt Lake City (UT) – Fluidx...
07/14/2026
Vascular Disease Management
Transarterial Chemoembolization
STRIDE-Based Regimens Plus TACE Improve Outcomes vs TACE Alone in Embolization-Eligible Hepatocellular Carcinoma
07/13/2026
Stephanie Holland
Results from the phase 3 EMERALD-3 trial demonstrated that combining STRIDE-based immunotherapy with TACE, with or without lenvatinib, significantly improved progression-free survival compared with TACE alone, supporting a potential new...
Results from the phase 3 EMERALD-3 trial demonstrated that combining STRIDE-based immunotherapy with TACE, with or without lenvatinib, significantly improved progression-free survival compared with TACE alone, supporting a potential new...
Results from the phase 3...
07/13/2026
Vascular Disease Management
Peripheral Intervention
3-Year DETOUR2 Results Demonstrate Sustained Symptom Relief and Limb Preservation in Complex SFA Disease
07/09/2026
Data from one of the first studies in long-segment (>30 cm) FP disease show durable patency, low reintervention rate, and high limb salvage through 36 months.
Data from one of the first studies in long-segment (>30 cm) FP disease show durable patency, low reintervention rate, and high limb salvage through 36 months.
Data from one of the first...
07/09/2026
Cath Lab Digest
Thrombectomy for Stroke
First Patient Enrolled in Penumbra’s FORWARD Study Evaluating Mechanical Thrombectomy and Computer Assisted Vacuum Thrombectomy for Distal Acute Ischemic Stroke
07/07/2026
ALAMEDA, Calif. - Penumbra, Inc. announced the initiation of its FORWARD study, an international, real world prospective, multi-center study. The study will collect safety and efficacy data on mechanical thrombectomy, including computer...
ALAMEDA, Calif. - Penumbra, Inc. announced the initiation of its FORWARD study, an international, real world prospective, multi-center study. The study will collect safety and efficacy data on mechanical thrombectomy, including computer...
ALAMEDA, Calif. - Penumbra, Inc....
07/07/2026
Cath Lab Digest
Embolization
Fluidx Announces Continued Clinical Success with ULTRA Embolic Gel
07/02/2026
SALT LAKE CITY, UT — July 02, 2026 — Fluidx Medical Technology, Inc. today announced that its ULTRA Embolic Device continues to see clinical success and was most recently used to treat a large, right-sided renal cell carcinoma (RCC) tumor at...
SALT LAKE CITY, UT — July 02, 2026 — Fluidx Medical Technology, Inc. today announced that its ULTRA Embolic Device continues to see clinical success and was most recently used to treat a large, right-sided renal cell carcinoma (RCC) tumor at...
SALT LAKE CITY, UT — July 02,...
07/02/2026
Vascular Disease Management

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use